Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-29
2010-06-22
Stockton, Laura L. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S388000
Reexamination Certificate
active
07741493
ABSTRACT:
The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II:wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.
REFERENCES:
patent: 4308277 (1981-12-01), Ferrini et al.
patent: 5106845 (1992-04-01), Carr et al.
patent: 54-112864 (1979-09-01), None
patent: 2-83372 (1990-03-01), None
patent: WO 99/29660 (1999-06-01), None
patent: WO 99/29661 (1999-06-01), None
patent: WO 99/29686 (1999-06-01), None
patent: WO 00/61569 (2000-10-01), None
patent: WO 01/44213 (2001-06-01), None
patent: WO 01/46200 (2001-06-01), None
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227.
Vippagunta et al., Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26.
Isobe et al., Journal of Organic Chemistry, 2000, 65(23), pp. 7774-7778.
A. D. Michel, et. al., Antagonist Effects on Human P2X7 Receptor-Mediated Cellular Accumulation of YO-PRO-1, British Journal of Pharmacology (2000, pp. 513-520, vol. 130).
B. J. Gu, et. al., Expression of P2X7 Purinoceptors on Human Lymphocytes and Monocytes: Evidence for Nonfunctional P2X7 Receptors, Am J. Physiol Cell Physiol (2000, pp. C1189-1197, vol. 279).
David G. Perregaux, et. al., ATP Acts As an Agonist to Promote Stimulus-Induced Secretion of IL-1 Beta and IL-18 in Human Blood, The Journal of Immunology (2000, pp. 4615-4623, vol. 165).
Davide Ferrari, et. al., Extracellular ATP Triggers IL-1Beta Release by Activating the Purinergic P2Z Receptor of Human Macrophages, The Journal of Immunology (1997, pp. 1451-1458, vol. 159).
Davide Ferrari, et. al., Purinergic Modulation of Interleukin-1Beta Release From Microglial Cells Stimulated With Bacterial Endotoxin, Journal Exp. Med (1997, pp. 579-582, vol. 185, No. 3).
Francesco Di Virgilio, et. al., The P2Z Purinoceptor: an Intriguing Role in Immunity, Inflammation and Cell Death, Immunology Today (1995, pp. 524-528, vol. 16, No. 11).
Geoffrey Burnstock, et. al., P2 Purinergic Receptors: Modulation of Cell Function and Therapeutic Potential, The Journal of Pharmacology and Experimental Therapeutics (2000, pp. 862-869, vol. 295).
M. Schon, et. al., Pathogenic Function of IL-1 Beta in Psoriasiform Skin Lesions of Flaky Skin (fsn/fsn) Mice, Clin Exp. Immunol (2001, pp. 505-510, vol. 123).
Martin G. Schwacha, et. al., Macrophages and Post-Burn Immune Dysfunction, Elsevier Science Ltd (2003, pp. 1-14, vol. 29).
Michael Williams, et. al., P2- Purinoceptors: Advances and Therapeutic Opportunities, Exp. Opin. Invest. Drugs (1995, pp. 925-934, vol. 4, No. 10).
Mike Solle, et. al., Altered Cytokine Production in Mice Lacking P2X7 Receptors, The Journal of Biological Chemistry (2001, pp. 125-132, vol. 276, No. 1).
Moriz Von Rauch, et. al., Effects of C2-Alkylation, N-Alkylation, and N,N'-Dialkylation on the Stability and Estrogen Receptor Interaction of (4R,5S)/(4S,5R)-4.5-Bis (4-Hydroxyphenyl)-2-Imidazolines, J. Med. Chem (2004, pp. 915-927, vol. 47).
Muller, W., et. al., Darstellung Neuer -Imidazolin-Derivate, Chemische Berichte (1951), vol. 84, pp. 71-76.
N. Kanda, et. al., The Skin Fungus-Induced Th1-and Th2-Related Cytokine, Chemokine and Prostraglandin E2 Production in Peripheral Blood Mononuclear Cells From Patients With Atopic Dermatitis and Psoriasis Vulgaris, Clin Exp Allergy (2002, pp. 1243-1250, vol. 32).
Richard J. Griffiths, et. al., ATP Induces the Release of IL-1 From LPS-Primed Cells In Vivo, The Journal of Immunology (1995, pp. 2821-2828, vol. 154).
S. Jeffrey Dixon, et. al., P2 Purinergic Receptors on Osteoblasts and Osteoclasts: Potential Targets for Drug Development, Drug Development Research (2000, pp. 187-200, vol. 49).
Gross Alexandre
Ma Liang
McGarry Daniel G.
Merriman Gregory H.
Rampe David
Aventis Pharmaceuticals Inc.
Gupta Balaram
Stockton Laura L.
LandOfFree
Heterocyclic compounds as P2X7 ion channel blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds as P2X7 ion channel blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds as P2X7 ion channel blockers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4168556